RAS is one of the most well-known proto-oncogenes. Its gain-of-function mutations occur in
approximately 30% of all human cancers. As the most frequently mutated RAS isoform …

Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …

How the KRAS oncogene drives cancer growth remains poorly understood. Therefore, we
established a systemwide portrait of KRAS-and extracellular signal–regulated kinase (ERK) …

Summary KRAS G12C was recently identified to be potentially druggable by allele-specific
covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP) …

Tissue damage increases the risk of cancer through poorly understood mechanisms. In
mouse models of pancreatic cancer, pancreatitis associated with tissue injury collaborates …

To delineate the mechanisms by which the ERK1 and ERK2 mitogen-activated protein
kinases support mutant KRAS–driven cancer growth, we determined the ERK-dependent …

Regulatory networks that maintain functional, differentiated cell states are often dysregulated
in tumor development. Here, we use single-cell epigenomics to profile chromatin state …

Primary/intrinsic and treatment-induced acquired resistance limit the initial response rate to
and long-term efficacy of direct inhibitors of the KRASG12C mutant in cancer. To identify …

Colorectal cancer (CRC) is the third most common cause of cancer mortality worldwide.
Approximately 40% of CRC patients are KRAS sequence variation, including KRAS G13D …

Inhibitors targeting KRASG12C, a mutant form of the guanosine triphosphatase (GTPase)
KRAS, are a promising new class of oncogene-specific therapeutics for the treatment of …